Split History
ETFs Holding MRNS »    MRNS Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare seizure disorders. Co.'s clinical stage product candidate, ganaxolone, is a positive allosteric modulator of gamma-aminobutyric acid (GABAA) being developed in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. Ganaxolone acts at both synaptic and extrasynaptic GABAA receptors and exhibits anti-seizure, antidepressant and anxiolytic properties. According to our MRNS split history records, Marinus Pharmaceuticals has had 1 split.
MRNS split history picture
Marinus Pharmaceuticals (MRNS) has 1 split in our MRNS split history database. The split for MRNS took place on September 23, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of MRNS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.

When a company such as Marinus Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the MRNS split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Marinus Pharmaceuticals shares, starting with a $10,000 purchase of MRNS, presented on a split-history-adjusted basis factoring in the complete MRNS split history. MRNS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 07/31/2014
End date: 06/22/2021
Start price/share: $32.00
End price/share: $18.41
Dividends collected/share: $0.00
Total return: -42.47%
Average Annual Total Return: -7.70%
Starting investment: $10,000.00
Ending investment: $5,753.60
Years: 6.90
Date Ratio
09/23/20201 for 4
MRNS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MSON Split History
MTEM Split History
MYG Split History
MYGN Split History
MYL Split History
MYO Split History
NAVB Split History
NBS Split History
NBY Split History
NEOG Split History

Also explore: MRNS shares outstanding history

BetaPro NASDAQ-100 2x Daily Bull ETF (HQU)
BetaPro S&P 500 2x Daily Bull ETF (HSU)
BetaPro S&P/TSX Capped Energy 2x Daily Bull ETF (HEU)
BetaPro S&P/TSX Capped Financials 2x Daily Bull ETF (HFU)
BetaPro S&P/TSX 60 2x Daily Bull ETF (HXU)
BetaPro Crude Oil Leveraged Daily Bull ETF (HOU)
Horizons Big Data & Hardware Index ETF (HBGD.U)
Horizons Big Data & Hardware Index ETF (HBGD)
Horizons NASDAQ-100 Index ETF (HXQ.U)
Horizons NASDAQ-100 Index ETF (HXQ)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MRNS Insider Buying

MRNS Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.